• Apyx Medical posted Q2 2026 revenue up 22.1% to $13.9 million, led by Surgical Aesthetics up 28.1% to $12.4 million.
• Net loss attributable to stockholders narrowed to $3.2 million; loss per share improved to $0.07.
• Adjusted EBITDA loss (non-GAAP) narrowed to $0.7 million as gross margin rose 1.6 percentage points to 63.9%.
• Expanded FDA 510(k) clearance added power liposuction for AYON; limited launch began, with initial commercial shipments in June 2026.
• Reaffirmed FY2026 revenue outlook of $59 million-$60 million, including Surgical Aesthetics $54 million-$55 million and OEM about $5 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apyx Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-026262), on August 06, 2026, and is solely responsible for the information contained therein.